ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: TH-OR044

Should RAAS Inhibition Be Discontinued in Children with Advanced CKD? Results of the 4C Study

Session Information

Category: Pediatric Nephrology

  • 1600 Pediatric Nephrology

Authors

  • Gracchi, Valentina, University Medical Center Groningen, Groningen, GRONINGEN, Netherlands
  • Van den Belt, Sophie, University Medical Center Groningen, Groningen, GRONINGEN, Netherlands
  • Lambers Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, GRONINGEN, Netherlands
  • Wuehl, Elke, University of Heidelberg, Heidelberg, Germany
  • de Zeeuw, Dick, University Medical Center Groningen, Groningen, GRONINGEN, Netherlands
  • Schaefer, Franz S., University of Heidelberg, Heidelberg, Germany

Group or Team Name

  • 4C Study group
Background

RAAS inhibition (RAASi) is used for renoprotection in children with Chronic Kidney Disease (CKD). RAASi is sometimes discontinued in advanced stages of CKD. We studied the reasons and impact of RAASi discontinuation on important markers of CKD progression and on eGFR decline in the Cardiovascular Comorbidity in Children with CKD (4C) study.

Methods

69 children with CKD (67% male, mean age 13.7 years, mean eGFR 27 ml/min/1.73m2) who discontinued RAASi during prospective follow-up were studied. Initial 6-month changes in blood pressure, albuminuria and potassium after discontinuation were assessed. The rate of eGFR decline (eGFR slope) during a median of 1.9 years before and 1.2 years after discontinuation were estimated using a linear mixed effects model.

Results

Reported reasons for RAASi discontinuation were increase in serum creatinine (33%), hyperkalemia (23%), and symptomatic hypotension (17%). After discontinuation of RAASi, blood pressure and albuminuria increased whereas potassium decreased. eGFR loss accelerated after RAASi discontinuation from -1.5 (95%CI -2.4 to -0.6) during RAASi treatment to -3.9 (95%CI -5.1 to -2.6) ml/min/1.73m2 per year (p=0.005). In a matched control group of children who continued RAASi, renal function decline was stable before and after timepoint of matching (eGFR slope -1.8 (95%CI -2.6 to -1.1) versus -1.2 (95%CI -2.0 to -0.4) ml/min/1.73m2/year; p=0.30; Figure).

Conclusion

Discontinuation of RAASi in children with CKD is associated with an acceleration of renal function decline. These results indicate that RAASi is nephroprotective even in advanced CKD and that stopping this therapy, even for good clinical reasons, should be weighed against a potential negative impact on long term renal function.

eGFR over time in patients who discontinued RAASi (blue) and matched controles (red). Grey area: 95%CI per group.